Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery

Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

1993 • 11,040 citations

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

2002 • 6,825 citations

ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction: Executive Summary and Recommendations

2000 • 4,662 citations

Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial

2005 • 2,476 citations

Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention

2005 • 2,039 citations

Risk of Cardiovascular Events Associated With Selective COX-2 Inhibitors

2001 • 1,716 citations

Renal Dysfunction after Myocardial Revascularization: Risk Factors, Adverse Outcomes, and Hospital Resource Utilization

1998 • 1,070 citations

ACC/AHA guidelines for the management of patients with unstable angina and non–st-segment elevation myocardial infarction

2000 • 959 citations

Coxibs and Cardiovascular Disease

2004 • 897 citations

Inflammatory Response to Cardiopulmonary Bypass

1997 • 869 citations

Aspirin and Mortality from Coronary Bypass Surgery

2002 • 663 citations

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

2002 • 517 citations

Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery

2003 • 403 citations

Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib

2001 • 358 citations

Mechanisms of myocardial reperfusion injury

1999 • 337 citations

Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets

2002 • 319 citations

Functional and Biochemical Evaluation of Platelet Aspirin Resistance After Coronary Artery Bypass Surgery

2003 • 290 citations

Risk of cardiovascular events associated with selective COX-2 inhibitors

2002 • 229 citations

Elevated plasma fibrinopeptide A and thromboxane B2 levels during cardiopulmonary bypass.

1980 • 187 citations

Parecoxib Sodium, a Parenteral Cyclooxygenase 2 Selective Inhibitor, Improves Morphine Analgesia and Is Opioid-sparing following Total Hip Arthroplasty

2003 • 154 citations

Cyclooxygenase-2 Inhibitors in Postoperative Pain Management

2003 • 119 citations

Thromboxane and prostacyclin changes during cardiopulmonary bypass with and without pulsatile flow

1982 • 118 citations

Shear-Induced Platelet Aggregation in Normal Subjects and Stroke Patients

1995 • 112 citations

Prostaglandin E2, prostacyclin, and thromboxane changes during nonpulsatile cardiopulmonary bypass in humans

1986 • 105 citations

Aspirin resistance after coronary artery bypass grafting

2001 • 103 citations

Effective Treatment of Laparoscopic Cholecystectomy Pain with Intravenous Followed by Oral COX-2 Specific Inhibitor

2004 • 102 citations

A double-blind, randomized comparison of intramuscularly and intravenously administered parecoxib sodium versus ketorolac and placebo in a post—oral surgery pain model

2001 • 100 citations

Analgesic effects of parecoxib following total abdominal hysterectomy † †Declaration of interest. The authors are grateful to Pharmacia for an educational grant for this trial.

2003 • 76 citations

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

2003 • 56 citations

Halt of Celebrex Study Threatens Drug's Future, Other Trials

2004 • 24 citations

Perturbations in laboratory values after coronary artery bypass graft surgery with cardiopulmonary bypass

2005 • 14 citations